The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ELCC 2022 | Lung cancer screening via biomarkers

Name: Lung cancer screening via biomarkers
Uploaded: 2022-03-28T00:00:00Z
Duration: 2 min 4 s
Description: Luis Montuenga, MD, Clinica Universidad de Navarra, Pamplona, Spain, discusses utilizing various molecular biomarkers in screening for lung cancer, including proteins circulating the blood and circulating tumor DNA (ctDNA), which can aid in defining risk levels of patients as low, intermediate, or high-risk. This interview took place during the virtual European Lung Cancer Congress 2022.

Luis Montuenga • 28 Mar 2022

ELCC 2022

Lung Cancer

Luis Montuenga, MD, Clinica Universidad de Navarra, Pamplona, Spain, discusses utilizing various molecular biomarkers in screening for lung cancer, including proteins circulating the blood and circulating tumor DNA (ctDNA), which can aid in defining risk levels of patients as low, intermediate, or high-risk. This interview took place during the virtual European Lung Cancer Congress 2022.